Insilico Medicine

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Insilico Medicine headquartered in Asia, operates in the Biotechnology, Artificial Intelligence (AI), Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $70.6B in funding across 176 round(s). With a team of 101-250 employees, Insilico Medicine is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Insilico Medicine, raised $300.0K. Discover more about their projects, partnerships, and impact on our platform.